AGS Xenograft Model Service for Gastric Cancer

The AGS xenograft model represents a well-established and extensively characterized preclinical platform for gastric adenocarcinoma research, enabling robust evaluation of novel therapeutic candidates in an immunocompromised host environment. Alfa Cytology specializes in the development and execution of AGS xenograft studies, delivering standardized, reproducible preclinical data to support your gastric cancer drug discovery and development programs with precision and reliability.

Overview of AGS Xenograft Model for Gastric Cancer

The AGS cell line-derived xenograft model is a widely utilized preclinical system for studying gastric adenocarcinoma, the fifth most common malignancy worldwide. Originally established from tumor fragments of an untreated patient, the AGS cell line retains key histopathological and molecular characteristics of human gastric cancer, including poorly differentiated adenocarcinoma morphology, epithelial origin confirmed by cytokeratin 8 positivity, and high proliferative activity indicated by Ki-67 expression exceeding 43%. The model demonstrates a tumor take rate of approximately 62.5% in immunodeficient mice, with a mean tumor doubling time of approximately 41 days and a latency period of around 30 days post-inoculation, providing a predictable timeline for therapeutic intervention studies.

Genetically, AGS cells harbor mutations in CTNNB1, PIK3CA, and KRAS, and exhibit p53 mutation positivity, making this model particularly suitable for evaluating targeted therapies against these oncogenic drivers. The xenograft tumors display high microvessel density and active angiogenesis, yet maintain epithelial integrity without evidence of epithelial-mesenchymal transition, as vimentin expression remains negative. The model has been successfully employed in monotherapy and combination therapy studies, including investigations of EGFR inhibitors, MEK inhibitors, and agents targeting the AMPK/PTEN/HSP90 axis, offering a versatile platform for mechanism-of-action studies and efficacy assessments in gastric cancer drug development.

Figure 1. Growth curve of gastric tumors during 100 days after inoculation of AGS cells. (Barati, Tahereh, et al., 2018)

Cell Line Information: AGS

The AGS cell line is a human gastric adenocarcinoma epithelial cell line with well-documented origins and molecular profiles. Below is a comprehensive summary of its characteristics:

Our Services

Alfa Cytology leverages the AGS xenograft platform to deliver comprehensive preclinical evaluation services for gastric cancer therapeutics. Our team ensures rigorous quality control, standardized tumor monitoring protocols, and customizable study designs---including monotherapy, combination therapy, and biomarker analysis---to accelerate your drug development pipeline with confidence and scientific rigor.

Workflow of AGS Xenograft Model Construction

The construction of the AGS xenograft model follows a systematic, multi-step protocol designed to ensure high viability, consistent tumor growth, and reproducible preclinical outcomes. The process begins with meticulous cell preparation and concludes with comprehensive endpoint analysis.

1. Cell Preparation and Quality Control: AGS cells are maintained under aseptic conditions in exponential growth phase. Prior to injection, cells are harvested using trypsin-EDTA, and viability is confirmed via trypan blue exclusion assay (>=98% viability required). Cell suspension density is adjusted to the appropriate concentration for inoculation.
2. Animal Selection and Acclimation: Immunocompromised mice (typically athymic BALB/c nude mice or NOD/SCID mice, 6-10 weeks old) are acclimated to the facility environment for a minimum of one week. Health status is monitored and documented before study initiation.
3. Tumor Cell Inoculation: Each mouse receives a subcutaneous injection of AGS cell suspension (typically 1x10^6 cells in 100-200 microL) into the flank or hind leg, often mixed with Matrigel to enhance engraftment efficiency. Injection sites are monitored for immediate adverse reactions.
4. Tumor Establishment and Monitoring: Injection sites are palpated three times weekly until palpable tumors are detected. Tumor dimensions are measured using digital calipers, and volumes are calculated using the formula: length x width^2 x 0.5. Tumor growth is plotted over time to establish baseline kinetics.
5. Randomization and Treatment Initiation: Upon reaching an average tumor volume of 50-150 mm^3, animals are randomized into treatment cohorts based on tumor size and body weight. The test compound is administered according to the predefined dosing schedule and route.
6. In-Life Monitoring: Tumor measurements and body weights are recorded three times weekly throughout the study period. General health observations, including signs of toxicity or distress, are documented daily to ensure animal welfare compliance.
7. Endpoint Determination: Studies are terminated when tumor volumes reach the institutional IACUC-predetermined limit (typically 2,000 mm^3), or at a predefined study duration. Mice are humanely euthanized according to approved protocols.
8. Necropsy and Sample Collection: A full necropsy is performed, and tumors are excised, weighed, and photographed. Tumor tissues and specified organs are collected for downstream analyses, including histopathology (H&E, IHC), gene expression, and protein analysis.
9. Data Analysis and Reporting: Tumor growth inhibition (TGI), tumor growth delay (TGD), and body weight change are calculated. Statistical analyses are performed to determine therapeutic efficacy, and a comprehensive study report is generated with all raw data and interpretive summaries.

Figure 2: Schematic workflow illustrating the derivation and construction of the AGS Xenograft Model at Alfa Cytology.

Case Study-AGS Xenograft Model Development

In a representative preclinical engagement, AGS cells were successfully engrafted into athymic nude mice to evaluate the anti-tumor efficacy of a novel targeted therapeutic candidate. Following subcutaneous inoculation, tumors were established with a predictable latency period and demonstrated consistent exponential growth kinetics. Upon randomization at approximately 100 mm^3, animals received the test compound or vehicle control according to a predefined dosing regimen. Preliminary data indicated a dose-dependent reduction in tumor volume compared to the control group, with acceptable tolerability profiles as assessed by body weight stability and clinical observation scores. Endpoint analyses, including H&E and IHC staining of excised tumors, revealed modulation of Ki-67 and CD34 expression, suggesting anti-proliferative and anti-angiogenic mechanisms. These findings demonstrate the utility of the AGS xenograft platform in generating actionable preclinical data to inform downstream development decisions. Detailed quantitative results and statistical outputs are available upon request and can be tailored to specific program requirements.

Why Choose Alfa Cytology?

Alfa Cytology is committed to delivering high-quality, reproducible preclinical data through rigorous scientific protocols and client-centric service models. Our AGS xenograft service is designed to accelerate your gastric cancer therapeutic development with the following advantages:

• Extensive experience in AGS xenograft model development with validated tumor growth kinetics and histopathological characterization.
• Customizable study designs accommodating monotherapy, combination therapy, dose-response, and biomarker-driven endpoints.
• Strict adherence to IACUC guidelines and AAALAC-accredited facility standards, ensuring ethical and compliant animal research practices.
• Comprehensive in-life monitoring with digital caliper measurements, body weight tracking, and detailed clinical observation records.
• Integrated endpoint analysis including histopathology, immunohistochemistry, gene expression, and protein profiling under one service roof.
• Dedicated project management with regular progress updates, transparent communication, and flexible scheduling to meet your timeline.
• Competitive turnaround times and cost-effective pricing structures without compromising data quality or scientific integrity.

Contact Us

Ready to advance your gastric cancer therapeutic program with a validated AGS xenograft model? Please reach out to us today via our inquiry form or email to learn more about our AGS Xenograft Model services.

For research use only. Not intended for any clinical use.